NDA 205555 · Novatech SA
Steritalc
Talc · Intrapleural
OrphanLast checked: Nov 20, 2026Latest source record: Jun 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
May 1, 2017
Approved uses
1
Original approval plus efficacy supplements
Registered trials
48
15 Phase 3, 3 recruiting
FAERS reports
420
411 serious, 108 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 25, 2025.
1.INDICATIONS AND USAGE 1.INDICATIONS AND USAGE 1.1 Malignant Pleural Effusion STERITALC is indicated to decrease the recurrence of malignant pleural effusions in symptomatic patients following maximal drainage of the pleural effusion. 1.2 Pneumothorax STERITALC is indicated in adults to decrease the recurrence of pneumothorax. ___________ INDICATIONS AND USAGE__ __________ STERITALC® is a sclerosing agent indicated: To decrease the recurrence of malignant pleural effusions in symptomatic patients following maximal drainage of the pleural effusion. (1.1) In adults to decrease the recurrence of pneumothorax. (1.2)
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 1, 2017 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLabelLetterReview
3 products under this application
- STERITALC · TALC 4GM/VIAL · POWDER, INTRAPLEURAL · Prescription
- STERITALC · TALC 2GM/VIAL · POWDER, INTRAPLEURAL · Prescription
- STERITALC · TALC 3GM/VIAL · POWDER, INTRAPLEURAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Talc" as an intervention, any sponsor and status, largest first.
- Metformin and Dietary Restriction to Prevent Age-related Morbid Events in People With Metabolic SyndromePivotal-lookingCompleted
Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoAcademic, hospital or other
NCT02960711 · 1,600 participants · Start Feb 2014 · Primary completion Jul 2019
Drug: Metformin Hydrochloride 850 MG Oral Tablet [Glucophage]; Ludipress, mg stereate, micronized hydrated silica, talcum · For: Metabolic Syndrome
Sites: Milan, Italy
- Adaptive COVID-19 Treatment Trial 2 (ACTT-2)Pivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT04401579 · 1,033 participants · Start May 8, 2020 · Primary completion Jul 31, 2020
Drug: Remdesivir; Baricitinib · For: COVID-19
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 71 sites in all
- Adaptive COVID-19 Treatment Trial 4 (ACTT-4)Pivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT04640168 · 1,010 participants · Start Dec 2, 2020 · Primary completion May 18, 2021
Drug: Baricitinib; Dexamethasone and 1 more · For: COVID-19
Sites: Birmingham, Alabama; Fresno, California; La Jolla, California · 72 sites in all
- Talc in Treating Patients With Malignant Pleural EffusionPivotal-lookingCompleted
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT00002622 · 501 participants · Start Dec 1994 · Primary completion Mar 2005
Drug: talc; Talc · For: Metastatic Cancer
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 241 sites in all
- Bleomycin, Doxycycline, or Talc in Treating Patients With Malignant Pleural EffusionsPivotal-lookingCompleted
Eastern Cooperative Oncology GroupResearch network
NCT00002872 · 480 participants (planned) · Start Jan 10, 1997 · Primary completion Feb 2003
Drug: bleomycin sulfate; doxycycline · For: Metastatic Cancer
- Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial CancerPivotal-lookingNot yet recruiting
Evergreen Therapeutics, Inc.Industry
NCT05077215 · 450 participants (planned) · Start Dec 2026 · Primary completion Dec 2027
Drug: EG-007; Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection and 1 more · For: Advanced Endometrial Cancer
- Phase IV Trial to Evaluate Efficacy of Alpha-Lipoic Acid in Treating Symptomatic Diabetic Polyneuropathy in EgyptPivotal-lookingCompleted
Eva PharmaIndustry
NCT05813496 · 430 participants · Start Oct 26, 2022 · Primary completion Aug 3, 2024
Drug: Alpha-Lipoic Acid (ALA); Placebo · For: Polyneuropathy, Diabetic
Sites: Alexandria, Egypt; Banī Suwayf, Egypt; Cairo, Egypt · 5 sites in all
- A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE TrialPivotal-lookingCompleted
CardresearchAcademic, hospital or other
NCT06128967 · 399 participants · Start Oct 18, 2023 · Primary completion Jul 1, 2025
Drug: Fluvoxamine Maleate 100 MG; Placebo and 1 more · For: Long COVID-19 Syndrome; Chronic Fatigue Syndrome
Sites: Belo Horizonte, Brazil; Brumadinho, Brazil; Governador Valadares, Brazil · 6 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- exposure to chemical pollution305
- pain257
- anxiety222
- injury198
- mesothelioma176
- disability130
- emotional distress92
- quality of life decreased86
- deformity78
- mesothelioma malignant57
- epithelioid mesothelioma38
- pleural mesothelioma malignant28
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2007 | 2 |
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2014 | 5 |
| 2015 | 1 |
| 2016 | 7 |
| 2017 | 4 |
| 2018 | 8 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 17 |
| 2022 | 4 |
| 2023 | 74 |
| 2024 | 283 |
| 2025 | 4 |
| 2026 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Management of Malignant Pleural Effusions. An Official ATS/STS/STR Clinical Practice Guideline.
Feller-Kopman DJ, Reddy CB, DeCamp MM, et al. · Am J Respir Crit Care Med 2018 · Research Support, Non-U.S. Gov't, Systematic Review
- Investigation on factors associated with ovarian cancer: an umbrella review of systematic review and meta-analyses.
Tanha K, Mottaghi A, Nojomi M, et al. · J Ovarian Res 2021 · Systematic Review
- [Pulmonary complications in cocaine users].
Underner M, Peiffer G, Perriot J, et al. · Rev Mal Respir 2020 · Systematic Review
- Outpatient Talc Administration by Indwelling Pleural Catheter for Malignant Effusion.
Bhatnagar R, Keenan EK, Morley AJ, et al. · N Engl J Med 2018 · Comparative Study, Randomized Controlled Trial
- Talc slurry pleurodesis in patients with secondary intractable pneumothorax: A phase 2 study.
Saka H, Oki M, Yamauchi Y, et al. · Respir Investig 2024 · Clinical Trial, Phase II
- Talc Pleurodesis: A Medical, Medicolegal, and Socioeconomic Review.
Baiu I, Yevudza E, Shrager JB · Ann Thorac Surg 2020 · Systematic Review
Sponsor: Novatech SA
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.